deracoxib

Modify Date: 2024-01-04 07:39:27

deracoxib structure	Common Name	deracoxib
	CAS Number	169590-41-4	Molecular Weight	397.372
	Density	1.5±0.1 g/cm3	Boiling Point	575.5±60.0 °C at 760 mmHg
	Molecular Formula	C₁₇H₁₄F₃N₃O₃S	Melting Point	N/A
	MSDS	N/A	Flash Point	301.9±32.9 °C

Use of deracoxib

Deracoxib, a selective cyclooxygenase-2 inhibitor, is a non-narcotic, non-steroidal anti-inflammatory drug (NSAID). IC50 Value: 70 to 150 uM(inhibition of 3 osteosarcoma cell lines) [1]Target: COXin vitro: Concentration of deracoxib required for 50% inhibition of cell viability (IC50) was reached in all 3 osteosarcoma cell lines and ranged from 70 to 150 microM, whereas the IC50 for piroxicam was only reached in the POS cell line at 500 microM. Neither deracoxib nor piroxicam induced sufficient toxicity in fibroblasts to reach an IC50. Exposure of osteosarcoma cells to cytotoxic concentrations of deracoxib and piroxicam did not result in DNA fragmentation [1]. Concomitant treatment of cells with piroxicam and deracoxib resulted in significant induction of apoptosis at lower concentrations and accumulation of cells in the G /G phase. Significant cytotoxic effects exhibited by the combination of piroxicam and deracoxib against canine mammary carcinoma cells in vitro suggest an attractive approach for the treatment of canine mammary carcinoma [2].in vivo: Perioperative administration of deracoxib to dogs at 1-2 mg/kg/day for 3 days significantly improves analgesia in the postoperative surgical period after soft tissue surgery [3]. Dogs were treated PO with deracoxib at a dosage of 3 mg/kg/d (1.36 mg/lb/d) as a single-agent treatment for TCC. Tumor response was assessed via radiography, abdominal ultrasonography, and ultrasonographic mapping of urinary bladder masses. Toxic effects of deracoxib administration in dogs were assessed through clinical observations and hematologic and biochemical analyses. 24 dogs for which tumor response was assessed, 4 (17%) had partial remission, 17 (71%) had stable disease, and 3 (13%) had progressive disease; initial response could not be assessed in 2 of 26 dogs. The median survival time was 323 days. Median time to progressive disease was 133 days. Renal, hepatic, and gastrointestinal abnormalities attributed to deracoxib administration were noted in 4% (1/26), 4% (1/26), and 19% (5/26) of dogs, respectively [4].

Name	deracoxib
Synonym	More Synonyms

Description	Deracoxib, a selective cyclooxygenase-2 inhibitor, is a non-narcotic, non-steroidal anti-inflammatory drug (NSAID). IC50 Value: 70 to 150 uM(inhibition of 3 osteosarcoma cell lines) [1]Target: COXin vitro: Concentration of deracoxib required for 50% inhibition of cell viability (IC50) was reached in all 3 osteosarcoma cell lines and ranged from 70 to 150 microM, whereas the IC50 for piroxicam was only reached in the POS cell line at 500 microM. Neither deracoxib nor piroxicam induced sufficient toxicity in fibroblasts to reach an IC50. Exposure of osteosarcoma cells to cytotoxic concentrations of deracoxib and piroxicam did not result in DNA fragmentation [1]. Concomitant treatment of cells with piroxicam and deracoxib resulted in significant induction of apoptosis at lower concentrations and accumulation of cells in the G /G phase. Significant cytotoxic effects exhibited by the combination of piroxicam and deracoxib against canine mammary carcinoma cells in vitro suggest an attractive approach for the treatment of canine mammary carcinoma [2].in vivo: Perioperative administration of deracoxib to dogs at 1-2 mg/kg/day for 3 days significantly improves analgesia in the postoperative surgical period after soft tissue surgery [3]. Dogs were treated PO with deracoxib at a dosage of 3 mg/kg/d (1.36 mg/lb/d) as a single-agent treatment for TCC. Tumor response was assessed via radiography, abdominal ultrasonography, and ultrasonographic mapping of urinary bladder masses. Toxic effects of deracoxib administration in dogs were assessed through clinical observations and hematologic and biochemical analyses. 24 dogs for which tumor response was assessed, 4 (17%) had partial remission, 17 (71%) had stable disease, and 3 (13%) had progressive disease; initial response could not be assessed in 2 of 26 dogs. The median survival time was 323 days. Median time to progressive disease was 133 days. Renal, hepatic, and gastrointestinal abnormalities attributed to deracoxib administration were noted in 4% (1/26), 4% (1/26), and 19% (5/26) of dogs, respectively [4].
Related Catalog	Research Areas >> Inflammation/Immunology
Target	COX-2
References	[1]. Royals, S.R., et al., Investigation of the effects of deracoxib and piroxicam on the in vitro viability of osteosarcoma cells from dogs. Am J Vet Res, 2005. 66(11): p. 1961-7. [2]. Ustun Alkan, F., et al., The effects of piroxicam and deracoxib on canine mammary tumour cell line. ScientificWorldJournal, 2012. 2012: p. 976740. [3]. Bienhoff, S.E., et al., Efficacy and safety of deracoxib for control of postoperative pain and inflammation associated with soft tissue surgery in dogs. Vet Surg, 2012. 41(3): p. 336-44. [4]. McMillan, S.K., et al., Antitumor effects of deracoxib treatment in 26 dogs with transitional cell carcinoma of the urinary bladder. J Am Vet Med Assoc, 2011. 239(8): p. 1084-9.

Density	1.5±0.1 g/cm3
Boiling Point	575.5±60.0 °C at 760 mmHg
Molecular Formula	C₁₇H₁₄F₃N₃O₃S
Molecular Weight	397.372
Flash Point	301.9±32.9 °C
Exact Mass	397.070801
PSA	95.59000
LogP	2.54
Vapour Pressure	0.0±1.6 mmHg at 25°C
Index of Refraction	1.610
Storage condition	-20℃

HS Code	2935009090

4,4-difluoro-1-...

CAS#:170570-77-1

~89%

deracoxib

CAS#:169590-41-4

Literature: G.D. Searle and Co. Patent: US5760068 A1, 1998 ;

4-Hydrazinobenz...

CAS#:17852-52-7

4,4-difluoro-1-...

CAS#:170570-77-1

~89%

deracoxib

CAS#:169590-41-4

Literature: G. D. Searle and Co. Patent: US6342510 B1, 2002 ; Location in patent: Page column 28 - 29 ;

ethyldifluoracetat

CAS#:454-31-9

3′-Fluoro-4′-me...

CAS#:455-91-4

deracoxib

CAS#:169590-41-4

Literature: US5892053 A1, ;

3′-Fluoro-4′-me...

CAS#:455-91-4

deracoxib

CAS#:169590-41-4

Literature: Journal of Medicinal Chemistry, , vol. 40, # 9 p. 1347 - 1365

Precursor 4
CAS#:170570-77-1 4,4-difluoro-1-... CAS#:17852-52-7 4-Hydrazinobenz... CAS#:454-31-9 ethyldifluoracetat CAS#:455-91-4 3′-Fluoro-4′-me...
DownStream 0

HS Code	2935009090
Summary	2935009090 other sulphonamides VAT:17.0% Tax rebate rate:9.0% Supervision conditions:none MFN tariff:6.5% General tariff:35.0%

deracoxib

Benzenesulfonamide, 4-[3-(difluoromethyl)-5-(3-fluoro-4-methoxyphenyl)-1H-pyrazol-1-yl]-

4-[3-(difluoromethyl)-5-(3-fluoro-4-methoxyphenyl)pyrazol-1-yl]benzenesulfonamide

4-(3-(Difluoromethyl)-5-(3-fluoro-4-methoxyphenyl)-1H-pyrazol-1-yl)benzenesulfonamide

4-[3-(Difluoromethyl)-5-(3-fluoro-4-methoxyphenyl)-1H-pyrazol-1-yl]benzenesulfonamide

Shanghai Jizhi Biochemical Technology Co., Ltd
China
Product Name: deracoxib
Price: ￥1166.0/100mg ￥506.0/25mg
Purity: 98.0%
Stocking Period: 2 Day
Contact: Liu jia

DC Chemicals Limited
China
Product Name: Deracoxib
Price: $200.0/1g
Purity: 98.0%
Stocking Period: 3 Day
Contact: Tony Cao

Zhejiang Hangyu API Co., Ltd
China
Product Name: Deracoxib
Price: ￥Inquiry/1kg
Purity: 99.5%
Stocking Period: Inquiry
Contact: Vinnie

Get all suppliers and price by the below link:

deracoxib suppliers

Price: ￥390/25mg

Reference only. check more deracoxib price

deracoxib

Use of deracoxib

Names

deracoxib Biological Activity

Chemical & Physical Properties

Safety Information

Synthetic Route

Precursor & DownStream

Customs

Synonyms